CSIMarket Company Name, Ticker, Customers, else..
 
Traws Pharma inc   (NASDAQ: TRAW)
 
Price: $0.5420 $-0.03 -4.912%
Day's High: $0.5860000252723694 Week Perf: -8.14 %
Day's Low: $ 0.54 30 Day Perf: -1.45 %
Volume (M): 54,215 52 Wk High: $ 3.27
Volume (M$): $ 0 52 Wk Avg: $1.61
Open: $0.57 52 Wk Low: $0.43



 Market Capitalization (Millions $) 9
 Shares Outstanding (Millions) 16
 Employees 17
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -17
 Cash Flow (TTM) (Millions $) -10
 Capital Exp. (TTM) (Millions $) 3

Business Description


Traws Pharma, Inc. is a clinical-stage biopharmaceutical company developing therapies targeting respiratory viral diseases. The company focuses on investigational antiviral agents effective against resistant virus strains, with product candidates designed for safety and simple dosing. After merging with Trawsfynydd Therapeutics, Inc., Traws Pharma expanded its focus to include treatments for influenza, COVID-19, and other infectious diseases. Its clinical programs include therapies for bird flu, seasonal influenza, COVID-19, and cancer.


   Company Address: 12 Penns Trail Newtown 18940 PA
   Company Phone Number: 759-3680   Stock Exchange / Ticker: NASDAQ TRAW


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Changes

Leadership Shake-Up at Traws Pharma Amid Promising Breakthrough in Bird Flu Treatment

Published Fri, Mar 28 2025 8:30 PM UTC

Traws Pharma in Transition: Charting a Course through Financial Struggles and Promising InnovationsNEWTOWN, Pa.—In a surprising move, Traws Pharma, Inc. (NASDAQ: TRAW), a clinical-stage biopharmaceutical company at the forefront of developing therapies against respiratory viral diseases, announced the retirement of its Chief Executive Officer, Dr. Werner Cautreels, effe...
Clinical Study

Breaking Ground Tivoxavir Marboxil Shows Promise as a Single-Dose Treatment for H5N1 Bird Flu,

Published Mon, Mar 24 2025 11:48 AM UTC

: Traws Pharma, Inc. has unveiled significant progress in its antiviral bird flu program, announcing positive topline results from a pivotal study utilizing tivoxavir marboxil (TXM). This investigational oral small molecule, designed to inhibit CAP-dependent endonucleases, demonstrates potential as a single-dose treatment against H5N1 avian influenza in non-human primates. T...
Clinical Study

Traws Pharma Pioneering Oral Therapeutics for Respiratory Viral Diseases in a Transforming Biopharmaceutical Landscape

Published Thu, Nov 14 2024 9:30 PM UTC

In a rapidly evolving biopharmaceutical sector, Traws Pharma, Inc. has emerged as a notable player, particularly within the sphere of oral therapeutics for respiratory viral diseases. The company, headquartered in Newtown, Pennsylvania, recently provided a comprehensive business update and unveiled its financial results for the third quarter of 2024. As Traws Pharma continue...
Clinical Study

Balancing Breakthroughs Traws Pharmas Influenza Promise Amid Financial Strains,

Published Tue, Oct 8 2024 11:30 AM UTC

Traws Pharma, a rising biopharmaceutical company, has recently released encouraging Phase 1 data for its investigational antiviral drug, Tivoxavir Marboxil. The novel agent, designed for single-dose treatment or prevention of both seasonal and pandemic influenza, demonstrated efficacy and safety in early clinical trials. However, despite these promising scientific developmen...
Clinical Study

Promising Phase 1 Findings for Ratutrelvir A Novel Oral Mpro Inhibitor for COVID-19 Treatment

Published Mon, Sep 30 2024 11:30 AM UTC

: The pharmaceutical landscape has been profoundly impacted by the emergence of COVID-19, necessitating rapid innovation in antiviral therapies. Traws Pharma’s recent announcement regarding the topline results from a Phase 1 clinical trial offers significant insights into the therapeutic potential of Ratutrelvir, an oral Mpro inhibitor aimed at combating COVID-19. This a...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 5.08
PEG (TTM) -

Financial Strength Current
Quick Ratio -
Working Capital Ratio 0.93
Leverage Ratio (MRQ) 5.78
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.3 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value 0.11 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -984,471
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.